¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"leukocyte adherence inhibition test"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® Mantoux test ÇÑ±Û ¸ÁÅä¿ì°Ë»ç
¼³¸í   
  ¼Ò¾Æ¿¡ ÁַΠ½Ç½ÃÇϴ °Ë»ç ¹æ¹ýÀ¸·Î, BCGÁ¢Á¾ÈÄ¿¡³ª È¤Àº °áÇÙ±Õ¿¡ ÇѹøÀ̶󵵠³ëÃâµÈ °æ¿ì¿¡ ¾ç¼º¹ÝÀÀÀ¸·Î ³ª¿Â´Ù. ¿ì¸®³ª¶ó¿¡¼­´Â »ýÈÄ 1°³¿ù¿¡ BCG¿¹¹æÁ¢Á¾À» ½ÃÇàÇϹǷΠ´ëºÎºÐ ¾ç¼ºÀ¸·Î ³ª¿À°Ô µÇ³ª, ÀÌ ¿¹¹æÁ¢Á¾À» ¹ÞÁö ¾ÊÀº »óÅ¿¡¼­ ¾ç¼ºÀ¸·Î ³ª¿À¸é, °áÇÙ±ÕÀǠħÅõ¸¦ ÀǽÉÇÒ ¼ö ÀÖ´Ù.
¿µ¹® stress test ÇÑ±Û ½ºÆ®·¹½º °Ë»ç
¼³¸í   
  Çù½ÉÁõÀÌ ÀϾ±â ½¬¿î È¯ÀÚ¿¡°Ô¼­ ±× Á¤µµ¸¦ ÆÇ´ÜÇϱâÀ§ÇØ ½ÃÇàÇÑ´Ù. ¹æ¹ýÀº °°Àº °÷¿¡¼­ È¯ÀÚ¸¦ ´Þ¸®µµ·Ï ÇÑ ´ÙÀ½, ¾ó¸¶ÀÇ ¼Óµµ¿¡¼­ Ç÷¾ÐÀÌ ¶³¾îÁö°í Çù½ÉÁõ Áõ»óÀÌ ³ªÅ¸³ª´Â°¡¸¦ °Ë»çÇÑ´Ù.
  
  ´ë°³ ½ÉÇÒ¼ö·Ï ³·Àº ¼Óµµ¿¡¼­µµ Áõ»óÀÌ »¡¸® ³ªÅ¸³­´Ù.
¿µ¹® visual field test ÇÑ±Û ½Ã¾ß°Ë»ç
¼³¸í   
  ´«À» ÇѰ÷¿¡ °íÁ¤½ÃŲ Ã¤, °üÂûÇÒ ¼ö Àִ ÁÖº¯°ø°£À» ½Ã¾ß¶ó ÇÑ´Ù. ½Ã¾ß¸¦ °Ë»çÇϴ °¡Àå °£´ÜÇÑ ¹æ¹ýÀº ´ë¸é°Ë»ç(confronting test)ÀÌ´Ù. À̰ÍÀº Çǰ˻çÀÚÀÇ ´«À» °Ë»çÀÚÀÇ ´«¿¡ ¸ÂÃ߾¸µµ·Ï ÇÏ¿© ´«À» °íÁ¤½ÃŲä, °Ë»çÀÚ°¡ ¼Õ°¡¶ô³¡À» À§ÂÊ, ¾Æ·¡ÂÊ, ¿ÞÂÊ, ¿À¸¥ÂÊ, ±×¸®°í ºñ½ºµëÈ÷ °æ»çÁø °÷ µîÀ¸·Î ¿Å°Üº¸¾Æ Çǰ˻çÀÚ°¡ °üÂûÇÒ ¼ö ÀÖ´ÂÁö ¿©ºÎ¸¦ Á¤Çϴ °Ë»ç¹ýÀÌ´Ù. À̺¸´Ù Á¤È®ÇÑ °Ë»ç¹ýÀº ÀÚµ¿½Ä ÄÄÇ»Åͽþ߰˻ç¹ýÀÌ ÀÖ´Ù. ´ë°³, ´«ÀÚüÀÇ ÀÌ»óÀÌ À־ ½Ã¾ß°Ë»ç¿¡¼­ ÀÌ»óÀÌ ³ª¿ÀÁö¸¸, À̿ܠ³úÀÇ ÀÌ»óÀ¸·Î ½Ã°¢ÀÇ Çü¼º°æ·Î¿¡ ÀÌ»óÀÌ À־ ¿ª½Ã ÀÌ»ó¼Ò°ßÀ» º¸ÀδÙ.
¿µ¹® Draw a person test ÇÑ±Û Àι°È­ ¼º°Ý°Ë»ç
¼³¸í   
  Àι°È­ ¼º°Ý°Ë»ç´Â Ã³À½¿¡´Â Áö´É°Ë»ç·Î °³¹ßµÇ¾ú°í, ±× ÈÄ¿¡´Â »ç¶÷ÀÇ ¹«ÀǽÄÀÇ ¿ä¼Ò¸¦ °Ë»çÇϴ ¹æ¹ýÀ¸·Î ¹ßÀüÇÏ¿´´Ù. °Ë»çÀç·á´Â Áö¿ì°³°¡ Àִ ¿¬Çʰú ¹éÁö¸¦ ÇǰËÀÚ¿¡°Ô ÁÖ°í, »ç¶÷À» ±×·Áº¸¶ó´Â Áö½Ã¸¦ Çϸç, °Ë»çÀڴ ±×¸®´Â ¼ø¼­¿Í Æò°¡¸¦ ±â·ÏÇϰí, ´Ù ±×¸° ÈÄ¿¡´Â ¸ÕÀú¿Í ´Ù¸¥ À̼ºÀ» ±×¸®µµ·Ï ÇÑ´Ù. ÀÌ °Ë»ç¿¡¼­ÀÇ ½ÅüÀÇ ¸ð¾çÀº °ð ÀھƻóÀ» ¹Ý¿µÇѴٴ ÀÔÀå, ±×¸²¿¡¼­ °­Á¶µÈ ±â°üÀº ÀÇ»ç¼ÒÅë¼ö´Ü, °ü³äÈ­, ¿å±¸Ã¼°è, ¼ºÀû ´É·Â, °¥µî, ÁÂÀý°æÇè, ¼ºÀå·Â µîÀ» ¹Ý¿µÇÑ´Ù°í ÇÑ´Ù. À̰ÍÀº ¾Æµ¿°ú ¼ºÀο¡°Ô °³º°Àû ¶Ç´Â Áý´ÜÀûÀ¸·Î ½Ç½ÃÇÒ ¼ö ÀÖ°í, °£ÆíÇϸ鼭µµ À¯ÀÍÇÑ °ÍÀÌ´Ù. ÀÓ»óÀûÀ¸·Î´Â ³úÀÇ ±âÁúÀû º¯È­¸¦ ¾Ë¾Æ³»±â À§ÇÑ ¸ñÀûÀ¸·Îµµ ¸¹ÀÌ ÀÌ¿ëµÈ´Ù.
¿µ¹® intelligence test ÇÑ±Û Áö´É°Ë»ç
¼³¸í   
  1905³â ÇÁ¶û½ºÀÇ ºñ³×°¡ Á¤½Å¹Ú¾à¾Æ¸¦ ÀϹݾƵ¿À¸·ÎºÎÅÍ ÆÇº°Çϱâ À§ÇÏ¿© ÀÛ¼ºÇÑ °ÍÀÌ Áö´É°Ë»çÀÇ ½ÃÀÛÀÌ´Ù. Áö´É°Ë»ç´Â ±×ÀÇ ¸ñÀûÀ¸·ÎºÎÅÍ ÀϹÝÀû Áö´É°Ë»ç¿Í Áø´Ü¿ë Áö´É°Ë»ç·Î ³ª´²Áö°í, ½Ç½Ã¹æ¹ý¿¡¼­ °³Àοë(°³º°½Ä)°ú Áý´Ü¿ë(´Üü½Ä)À¸·Î ºÐ·ùµÇ°í ¶Ç ¹®Á¦ÀÇ ³»¿ëÀ¸·ÎºÎÅÍ ¾ð¾î¼º°Ë»ç(A½Ä ¶Ç´Â ¥á½Ä)¿Í ºñ¾ð¾î¼º°Ë»ç(B½Ä ¥â½Ä)·Î ³ª´²Áø´Ù. Áö´É°Ë»çÀÇ °á°úÀǠǥ½Ã¹ýÀº Á¤½Å¿¬·É(mental age, MA), Áö´ÉÁö¼ö(intelligence quotient, IQ), Áö´ÉÆíÂ÷Ä¡(intelligence standard score, ISS)µîÀÌ ÀÖ´Ù. Áö´É°Ë»ç¿¡´Â ¿ª»çÀûÀ¸·Î ºñ³×½Ä°ú À°±º½ÄÀÇ µÎ °èÅëÀÌ ÀÖ´Ù. ºñ³×½ÄÀº °Ë»çÀÚ°¡ °³º°ÀûÀ¸·Î ÇÑ °³ ¹®Ç×¾¿ Áú¹®À» Çϸé ÀÌ¿¡ ´ëÇÏ¿© Çǰ˻çÀÚ°¡ ¸»À̳ª ÇൿÀ¸·Î ÀÀ´äÇϴ ¹æ¹ý(°³º°½Ä-¹®´ä½Ä)À̰í, À°±º½ÄÀº ÀϹÝÀûÀΠ¹æ½ÄÀ¸·Î´Â ÀμâµÈ ¹®Á¦¿ëÁö¸¦ »ç¿ëÇÏ¿© Çǰ˻çÀÚ°¡ ¼ÒÁ¤ÀÇ ½Ã°£ ³»¿¡ µÇµµ·Ï ¸¹ÀÌ ¹Ù¸£°Ô(½Ã°£Á¦Çѹý) È¸´äÀ» ±âÀÔÇÑ´Ù(Çʱâ¹ý). Çѱ¹ ÃÖÃÊÀÇ Áö´É°Ë»ç´Â 1954³â ¼­¿ï´ëÇб³ »ç¹ü´ëÇР±³À°½É¸®¿¬±¸½Ç¿¡¼­ Á¦ÀÛÇÑ °£Æí Áö´É°Ë»çÀÌ´Ù. °£Æí Áö´É°Ë»ç ÀÌÈÄ ´Ù¼öÀÇ Áý´Ü Áö´É°Ë»ç°¡ ÃâÇöÇÏ¿´´Âµ¥ ºñ±³Àû ÃÖ±Ù¿¡ Ç¥ÁØÈ­µÈ Áö´É°Ë»ç·Î´Â Çѱ¹Çൿ°úÇבּ¸¼Ò°¡ 1984³â¿¡ Àü±¹ °íµîÇб³ ÇлýÀ» ´ë»óÀ¸·Î Á¦ÀÛÇÑ KIT-S Áö´É°Ë»ç°¡ ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • endothelial leukocyte
    ³»ÇǹéÇ÷±¸
  • endothelial leukocyte adhesion molecule
    ³»ÇǹéÇ÷±¸ºÎÂøºÐÀÚ
  • eosinophil leukocyte
    È£»ê¹éÇ÷±¸, È£»ê±¸
  • globular leukocyte
    °ø¸ð¾ç¹éÇ÷±¸
  • granular leukocyte
    °ú¸³¹éÇ÷±¸
  • heterophilic leukocyte
    ÀÌ¿°»ö¹éÇ÷±¸
  • human leukocyte antigen
    »ç¶÷¹éÇ÷±¸Ç׿ø
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • leukocyte
    ¹éÇ÷±¸
  • leukocyte adhesion deficiency
    ¹éÇ÷±¸ºÎÂø°áÇÌ
  • leukocyte concentrate
    ¹éÇ÷±¸³óÃ๰
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • leukocyte-depleted
    ¹éÇ÷±¸Á¦°Å-
  • leukocyte-depleted blood product
    ¹éÇ÷±¸Á¦°ÅÇ÷¾×Á¦Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anticholinesterase test
    Ç×Äݸ°¿¡½ºÅ×¶óÁ¦°Ë»ç
  • antiglobulin test
    Çױ۷κҸ°°Ë»ç
  • antimicrobial susceptibility test
    Ç×±ÕÁ¦°¨¼ö¼º°Ë»ç
  • blood test
    Ç÷¾×°Ë»ç
  • blood coagulation test
    Ç÷¾×ÀÀ°í°Ë»ç
  • blood sugar test
    Ç÷´ç°Ë»ç
  • bronchial provocation test
    ±â°üÁöÀ¯¹ß°Ë»ç
  • contraction stress test
    ¼öÃàÀڱذ˻ç
  • Coombs' test
    (¢¡antiglobulin test) ÄñÁî°Ë»ç
  • creatinine clearance test
    Å©·¹¾ÆÆ¼´Ñû¼ÒÀ²°Ë»ç
  • D-xylose test
    Å©½Ç·Î¿À½º°Ë»ç
  • dip-stick test
    ¿ä½ÃÇèÁö°Ë»ç
  • estrogen challenge test
    ¿©¼ºÈ£¸£¸óºÎÇϰ˻ç
  • flashlight swinging test
    ±³´ëºÒºû°Ë»ç
  • glucose tolerance test
    ´çºÎÇϰ˻ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • basophilic leukocyte
    È£¿°±â¹éÇ÷±¸
  • broken leukocyte
    ±úÁø¹éÇ÷±¸
  • contracted leukocyte
    ¼öÃà¹éÇ÷±¸
  • differential leukocyte count
    °¨º°¹éÇ÷±¸°è»ê
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • leukocyte cream
    ¹éÇ÷±¸À¯Á¦
  • leukocyte adhesion deficiency
    ¹éÇ÷±¸ºÎÂø°áÇÌÁõ
  • endothelial leukocyte
    ³»ÇǹéÇ÷±¸
  • endothelial leukocyte adhesion molecule
    ³»ÇǼ¼Æ÷¹éÇ÷±¸ºÎÂøºÐÀÚ
  • eosinophil leukocyte
    È£»ê¼º¹éÇ÷±¸
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • globular leukocyte
    °ø¸ð¾ç¹éÇ÷±¸
  • granular leukocyte
    °ú¸³¹éÇ÷±¸
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • heterophilic leukocyte
    (¢¡heterophil) ÀÌ¿°»ö¹éÇ÷±¸
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test
    ÀúÁö½ÃÇè(îÁò­ãËúÐ).
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
  • inhibition test, antiglobulin
    Çױ۷κҸ° ¾ïÁ¦½ÃÇè, Çױ۷κҸ° ÀúÁö½ÃÇè
  • inhibition test, fluorescence
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • inhibition test, hemagglutination
    Ç÷±¸ÀÀÁý ¾ïÁ¦½ÃÇè, Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test, migration
    À¯ÁÖ¾ïÁ¦½ÃÇè, À¯ÁÖÀúÁö½ÃÇè
  • HLA => human leukocyte antigen
    ÀÎüÁ¶Á÷ÀûÇÕÇ׿ø<ÀÎü¹éÇ÷±¸Ç׿ø>
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • acidophilic leukocyte
    »êÈ£¼º ¹éÇ÷±¸(¡­ÛÜúìϹ), »êÈ£±¸(ß«û¿Ï¹).
  • acidophilic leukocyte
    È£»ê¼º¹éÇ÷±¸
  • acidophilic leukocyte
    »êÈ£¼º ¹éÇ÷±¸(?ËÑÌ´Ë´), »êÈ£±¸(Ë×Ì´Ë´).
  • acidophilic metamyelocyte juvenile acidophilic leukocyte
    È£»ê¼º´Ê°ñ¼ö¼¼Æ÷ ¾î¸°È£»ê¼º¹é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • agar gel precipitin inhibition test
    ÇÑõ°Öħ°­¼Ò ÀúÁö½ÃÇè(¡­ ˽áÈðæò­ãËúÐ).
  • agglutination inhibition test
    ÀÀÁý¾ïÁ¦½ÃÇè(¡­åäð¤ãËúÐ).
  • colony inhibition test
    Áý¶ôÇü¼º ÀúÁö½ÃÇè, ¼¼Æ÷±ºÇü¼º ÀúÁö½ÃÇè
  • complement fixation inhibition test
    º¸Ã¼°íÁ¤ÀúÇØ½ÃÇè(ÜÍô÷ͳïÒîÁúªãËúÐ).
  • complement fixation inhibition test
    º¸Ã¼°áÇÕÀúÇØ½ÃÇè(ÜÍô÷Ì¿ùêîÁúªãËúÐ).
  • fluoresence inhibition test
    Çü±¤¾ïÁ¦½ÃÇè, Çü±¤ÀúÁö½ÃÇè
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(¡­îÁò­ãËúÐ).
  • haemagglutination inhibition test
    Ç÷±¸ÀÀÁýÀúÁö½ÃÇè(?Ëø?ËàÌ´).
  • hemagglutination inhibition test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • hemagglutination inhibition test
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • hemagglutination-inhibition (HI) test
    Ç÷±¸ÀÀÁý ÀúÁö½ÃÇè
  • inhibition test
    ¾ïÁ¦½ÃÇè
  • inhibition test
    ÀúÁö½ÃÇè(îÁò­ãËúÐ).
  • inhibition test, agglutination
    ÀÀÁý¾ïÁ¦½ÃÇè, ÀÀÁýÀúÁö½ÃÇè
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • density inhibition
    "¹ÐµµÀúÇØ(ÚËÓøîÁúª), (ÔÒ) contact inhibition"
  • end-product inhibition
    Á¾»ê¹° ÀúÇØ (ðûß§ÚªîÁúª)
  • enzyme multiplicity feedback inhibition
    È¿¼Ò ´Ù¾ç¼º(ý£áÈÒýåÆàõ) µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • feedback inhibition
    µÇ¸ÔÀÓ ÀúÇØ(îÁúª)
  • hemagglutination inhibition
    "(Àû,îå)Ç÷±¸(úìϹ) ÀÀÁý ÀúÇØ(ëêó¢îÁúª)"
  • hyperbolic inhibition
    ½Ö°î¼± ÀúÇØ(äªÍØàÊîÁúª)
  • immunological inhibition
    ¸é¿ª ÀúÇØ(Øóæ¹îÁúª)
  • inhibition
    ÀúÇØ(îÁúª)
  • inhibition analysis
    ÀúÇØºÐ¼®(îÁúªÝÂà°)
  • inhibition coefficient
    ÀúÇØ°è¼ö(îÁúªÌõâ¦)
  • inhibition constant
    ÀúÇØ»ó¼ö(îÁúªßÈâ¦)
  • inhibition index
    ÀúÇØÁö¼ö(îÁúªò¦â¦)
  • inhibition ratio
    ÀúÇØÀ²(îÁúªëÒ)
  • inhibition zone
    ÀúÇØ¿ª(îÁúªæ´)
  • linear inhibition
    ¼±ÇüÀúÇØ(àÊû¡îÁúª)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • guaiac test
    °úÀ̾׽ÃÇè
  • laboratory test
    °Ë»ç
  • pivot shift test
    ÃßÃà º¯À§½ÃÇè
  • provocation test
    À¯¹ß½ÃÇè
  • provocative test
    À¯¹ß½ÃÇè
  • pulmonary function test
    Æó±â´É°Ë»ç
  • qualitative test
    Á¤¼º½ÃÇè
  • respiratory function test
    È£Èí±â´É°Ë»ç
  • routine test
    »ó¿ë Å×½ºÆ®
  • screening test
    ¼±º°°Ë»ç, ¿¹ºñ°Ë»ç
  • serologic test
    Ç÷û(ÇÐÀû)°Ë»ç
  • sigle blind test
    ´ÜÀϸͽÃÇè
  • skin test
    ÇǺÎ(¹ÝÀÀ)°Ë»ç
  • supression test
    ¾ïÁ¦°Ë»ç
  • test
    ½ÃÇè, °Ë»ç(¹ý)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PAT Pain Apperception Test; paroxysmal atrial tachycardia; patient; phenylaminotetrazole; physical abili...
MIT Massachusetts Institute of Technology; male impotence test; marrow iron turnover; melodic intonation...
EIC elastase inhibition capacity; enzyme inhibition complex
CAT California Achievement Test; capillary agglutination test; catalase; cataract; catecholamine; Childr...
TAT tetanus antitoxin; thematic apperception test; thematic aptitude test; thrombin-antithrombin complex...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
IAHA Immune adherence hemagglutination
LA Localised adherence
SRCA Secific Red Cell Adherence
HI Haemagglutination inhibition test
HIT Hemagglutination inhibition test
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • leukocyte count
    ¹éÇ÷±¸ ¼ö »êÁ¤
  • leukocyte differential count
    ¹éÇ÷±¸ ºÐÈ­
  • leukocyte electron microscope
    ¹éÇ÷±¸ ÀüÀÚÇö¹Ì°æ
  • leukocyte tranfusion
    ¹éÇ÷±¸ ¼öÇ÷
  • mononuclear leukocyte
    ´ÜÇÙ ¹éÇ÷±¸
  • motile leukocyte
    ¿îµ¿¼º ¹éÇ÷±¸
  • neutrophilic leukocyte
    È£Áß¼º ¹éÇ÷±¸
  • polymorphonuclear leukocyte
    ´ÙÇüÇÙ ¹éÇ÷±¸, ´ÙÇü ÇÙ±¸
    ÇÙÀÌ ¿©·¯ °³·Î °¥¶óÁ® ÀÖ´Â ¹éÇ÷±¸. È£Áß±¸, È£¿°±â±¸, È£»ê±¸°¡ ÀÖ´Ù.
  • allogeneic inhibition
    µ¿Á¾ ÀÌÇü ¾ïÁ¦
  • antagonistic inhibition
    ±æÇ×±Ù ¾ïÁ¦, ±æÇ×Àû ¾ïÁ¦, ±æÇ×Àû ÀúÇØ
  • antidromic inhibition
    ¿ª¹æÇ⼺ ¾ïÁ¦
  • competitive inhibition
    °æÀïÀû ¾ïÁ¦, °æÇÕ¼º ¾ïÁ¦
    ¾î¶² ¼ö¿ëü¿¡ ´ëÇØ °áÇÕ·ÂÀÌ Å« ¹°ÁúÀÌ »ó´ëÀûÀ¸·Î °áÇÕ·ÂÀÌ ¾àÇÑ ´Ù¸¥ ¹°ÁúÀÇ °áÇÕÀ» ¾ïÁ¦ÇÏ´Â °Í.
  • cyto- ¼¼Æ÷¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    cyto-inhibition

    ¼¼Æ÷ ¾ïÁ¦ ÀÛ¿ë
    ޽ÄÇÑ ¼¼±Õ ¶Ç´Â ¹ÙÀÌ·¯½º¸¦ ¿ëÇØÇϰųª È­Çпä¹ýÁ¦¿¡ ÀÇÇÑ È­ÇÐÀû ÆÄ±«·ÎºÎÅÍ ¹æ¾îÇÏ´Â ½Ä ¼¼Æ÷ÀÇ ÀÛ¿ë.
  • enzyme inhibition
    È¿¼Ò ¾ïÁ¦
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
macrophage inhibition factor <cytokine> A group of lymphokines (including a 14 kD glycoprotein) produced by activated T lymphocytes that reduces macrophage mobility and probably increases macrophage macrophage adhesion.
(18 Nov 1997)
reactive inhibition Tendency toward a lessened strength of response due to practice or activity. It is independent of the effect of reward and is a direct function of time interval since the last response and the number of preceding responses.
(12 Dec 1998)
reciprocal inhibition Contraction in a muscle is accompanied by a loss of tone or by relaxation in the antagonistic muscle.
Synonym: reciprocal inhibition.
(05 Mar 2000)
reflex inhibition A situation in which sensory stimuli decrease reflex activity.
(05 Mar 2000)
cell migration inhibition Phenomenon of cell-mediated immunity measured by in vitro inhibition of the migration or phagocytosis of antigen-stimulated leukocytes or macrophages. Specific assays have been developed to estimate levels of migration-inhibitory factor, immune reactivity against tumour-associated antigens, and immunosuppressive effects of infectious microorganisms.
(12 Dec 1998)
central inhibition <physiology> Suppression or diminution of outgoing impulses from a reflex centre.
(05 Mar 2000)
residual inhibition The inhibition or suppression of tinnitus by use of a sound-generating device (residual inhibitor) which masks the sounds of tinnitus and produces a residual sound-inhibiting effect when the device is turned off.
(05 Mar 2000)
retroactive inhibition The partial or complete obliteration of memory by a more recent event, particularly new learning.
Compare: proactive inhibition.
(05 Mar 2000)
Wedensky inhibition Inhibition of muscle response resulting from application of a series of rapidly repeated stimuli to the motor nerve where slower frequency of stimulation results in muscle response.
(05 Mar 2000)
competitive inhibition <chemistry> Inhibitor that occupies the active site of an enzyme or the binding site of a receptor and prevents the normal substrate or ligand from binding.
at sufficiently high concentration of the normal ligand inhibition is lost: the Km is altered by the competitive inhibitor, but the Vmax remains the same.
(05 Jan 1998)
contact inhibition The inhibition of continued growth and division of a cell or colony due to physical contact with other cells or colonies. The stopping of continued growth when a certain density of cells has been reached.
The momentary stopping of all movement when a mobile cell runs into another cell.
(09 Oct 1997)
contact inhibition of growth See: density dependent inhibition.
(18 Nov 1997)
contact inhibition of movement Reaction in which the direction of motion of a cell is altered following collision with another cell. In heterologous contacts both cell may respond (mutual inhibition) or only one (nonreciprocal). Type I contact inhibition involves paralysis of the locomotory machinery, Type II is a consequence of adhesive preference for the substratum rather than the dorsal surface of the other cell.
(18 Nov 1997)
contact inhibition of phagocytosis Phenomenon described in sheets of kidney epithelial cells that, when confluent, lose their weak phagocytic activity, probably because of a failure of adhesion of particles to the dorsal surface in the absence of ruffles.
(18 Nov 1997)
haemagglutination inhibition A variation of the haemagglutination technique. Some viral antigens, when coated on erythrocytes, spontaneously cause agglutination in the absence of antibody. In these situations, the specific antigen-antibody reaction actually prevents the agglutination of reagent RBCs. Haemagglutination inhibition cannot differentiate between isotypes of specific antibodies (IgG, IgA or IgM) although positive haemagglutination inhibition analysis of specimens treated with Staphylococcus aureus Protein A (discussed above under coagglutination) to remove the IgG isotype antibodies has been used to imply the presence of specific IgM antibodies to the specific viral antigen. The crude quantitation of the specific antibodies is possible using serial dilution (titre).
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Wassermann test
    ¹Ù¼­¸¸ °Ë»ç(¹ÝÀÀ);¸Åµ¶ÀÇ Ç÷û Áø´Ü
  • achievement test
    Çз°˻ç
  • acid test
    »ê½ÃÇè;¾ö¹ÐÇѽÃÇè
  • alpha test
    Áö´ÉÅ×½ºÆ®
  • blood test
    Ç÷¾×°Ë»ç
  • breath test
    ÁÖ±â°Ë»ç
  • captive test (firing)
    (¹Ì»çÀÏ.·ÎÄÏ ¿£ÁøµîÀÇ)Áö»ó ºÐ»ç ½ÃÇè
  • cartoon test
    ¾àÈ­ Å×½ºÆ®
  • completion test
    ¿Ï¼ºÇü Å×½ºÆ®
  • doping test
    ±ÝÁö ¾à¹° °Ë»ç
  • doublebline test
    ÀÌÁß¸Í °Ë»ç¹ý(½Å¾à È¿°úÀÇ °Ë»ç¹ý)
  • driving test
    ¿îÀü ¸éÇã ½ÃÇè
  • drop test
    ³«ÇÏ ½ÃÇè(Å×½ºÆ®)
  • fatigue test
    ÇÇ·Î ½ÃÇè
  • film test
    ¿µÈ­ ¹è¿ì Áö¸ÁÀÚÀÇ Ä«¸Þ¶ó Å×½ºÆ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á